Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761721 | 0.89 | ALDH1A1 (0.48) | ALDH1A1LMNA | |
| SCHEMBL7761443 | 0.89 | ALDH1A1 (0.48) | ALDH1A1LMNA | |
| SCHEMBL7662112 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MEN1LMNABLMHBB | |
| SCHEMBL7658497 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MEN1LMNABLMHBB | |
| SCHEMBL7768788 | 0.79 | ALDH1A1 (0.52) | ALDH1A1 | |
| Potassium Ion SCHEMBL7774839 | 0.79 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL7663993 | 0.79 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL7662206 | 0.79 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL13685884 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HIF1A | |
| SCHEMBL2015730 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001028975-A2 | METHOD FOR PRODUCTION OF 3-NITRYLOXY-2,2-BIS(NITRYLOXYMETHYL)-PROPANAL | ALPHARMA-ISIS GMBH & CO. KG (DE) | 2001-04-26 | — | — | WO | claimed |
| US-6180664-B1 | CARDIOVASCUALR DISORDERS; IMPOTENCY | ISIS PHARMA GMBH (DE) | 2001-01-30 | — | — | US | claimed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1883614-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1877374-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1861093-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1858525-A2 | ORGANIC NITRIC OXIDE DONOR SALTS OF ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007123818-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-6365611-B1 | HYDROPHILIC NITRATE VASODILATORS | ISIS PHARMA GMBH (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1087926-A2 | ANALYTIC SUBSTRATES AND ANTIOXIDATIVE AGENTS | Alpharma-Isis GmbH & Co. KG (DE) | 2001-04-04 | — | — | EP | disclosed |
| US-6180664-B1 | CARDIOVASCUALR DISORDERS; IMPOTENCY | ISIS PHARMA GMBH (DE) | 2001-01-30 | — | — | US | disclosed |
| US-6100263-A | CONTROLLING ANIMAL PESTS OR HARMFUL FUNGI; 2-METHOXYIMINO-2-(2'-(1?-METHYL,1?-(1?'-(6??-(4??'-CHLOROPHENYL) -HEXYLOXYIMINO) ,2?',2?'-DIMETHYLPROPYL))IMINOOXYMETHYL)-PHENYLACETIC ACID MONOMETHYLAMIDE, FOR EXAMPLE | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-08 | — | — | US | disclosed |
| EP-1009730-A1 | NEW PENTAERYTHRITOL DERIVATIVES, THEIR PRODUCTION AND USE AND INTERMEDIATES FOR THEIR SYNTHESIS | ISIS PHARMA GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| EP-0988282-A2 | NOVEL PENTAERYTHRITE DERIVATIVES, THE PRODUCTION AND USE THEREOF AND INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF THE SAME | ISIS PHARMA GMBH (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999067430-A2 | ANALYTIC SUBSTRATES AND ANTIOXIDATIVE AGENTS | ALPHARMA-ISIS GMBH & CO. KG (DE) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998056759-A2 | NOVEL PENTAERYTHRITE DERIVATIVES, THE PRODUCTION AND USE THEREOF AND INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF THE SAME | ISIS PHARMA GMBH (DE) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998015521-A1 | NEW PENTAERYTHRITOL DERIVATIVES, THEIR PRODUCTION AND USE AND INTERMEDIATES FOR THEIR SYNTHESIS | ISIS PHARMA GMBH (DE) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | ALDH1A1 630/4885MEN1 4231/4885LMNA 4765/4885 |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | ALDH1A1 1240/4885MEN1 2078/4885LMNA 1935/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | ALDH1A1 1202/4885MEN1 2094/4885LMNA 2062/4885 |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NOS1, NOS2, NOS3 | ALDH1A1 2518/4885MEN1 2233/4885LMNA 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.